BVS Bioventus, Inc.
Price Chart
Executive Summary
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line with the $155.4M estimate). The miss is notable given the company's 89% analyst buy rating, but the stock's historical T+20 win rate on directional calls is only 33%, suggesting limited follow-through. The press release focuses on an upcoming conference appearance, not guidance or operational details, leaving the miss as the primary takeaway.
Actionable Insight
The EPS miss is significant and likely to pressure the stock near-term. Monitor the upcoming Goldman Sachs conference for any guidance updates or strategic commentary that could clarify the miss. Given the low historical win rate on BVS directional calls, consider a cautious approach until more context emerges.
Key Facts
- Q1 2026 EPS of $0.15 missed consensus of $0.22 by 30.6%
- Revenue of $155.4M was in line with consensus of $155.4M
- No guidance update or operational commentary provided in the release
- CFO to present at Goldman Sachs Global Healthcare Conference on June 8, 2026
Financial Impact
EPS miss of $0.07 per share vs consensus, representing a 30.6% shortfall
Risk Factors
- No guidance or operational context provided, leaving the miss unexplained
- Historical T+20 win rate on BVS directional calls is only 33%, suggesting limited predictive value
- Potential for further downside if the miss reflects broader operational issues
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304982 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $8.83 awaiting T+1 | awaiting T+1 | — | $8.51 (+3.62%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $8.11 $8.55 | ▼ −5.43% | ▼ −6.12% | $8.51 (−4.93%) |
|
May 21, 2026
24d ago
|
8-K
| $9.28 $9.02 | ▼ −2.80% | ▼ −3.39% | $8.51 (−8.30%) |
|
May 8, 2026
5w ago
|
Court Ruling
| $10.50 $10.19 | ▼ −2.95% | ▼ −3.18% | $8.51 (−18.95%) |
|
May 6, 2026
5w ago
|
8-K
| $10.92 $10.65 | ▼ −2.47% | ▼ −2.14% | $8.51 (−22.07%) |
|
May 6, 2026
5w ago
|
Press Release
| $10.92 $10.65 | ▼ −2.47% | ▼ −2.14% | $8.51 (−22.07%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $9.67 $9.87 | ▲ +2.07% | ▲ +1.05% | $8.51 (−12.00%) |
|
Apr 22, 2026
7w ago
|
DEFA14A
| $9.77 $9.71 | ▼ −0.61% | ▼ −0.22% | $8.51 (−12.90%) |
|
Mar 5, 2026
14w ago
|
8-K
| $9.10 $8.41 | ▼ −7.58% | ▼ −6.27% | $8.51 (−6.48%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $9.10 $8.41 | ▼ −7.58% | ▼ −6.27% | $8.51 (−6.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access